Abstract：
In this study, a novel bio-composite material that allow sustained release of plant derived antimicrobial compound was developed for the biomedical applications to prevent the infections caused by microorganisms resistant to commercial antimicrobials agents. With this aim, bacterial cellulose (BC)-p(HEMA) nanocomposite film that imprinted with eugenol (EU) via metal chelated monomer, MAH was prepared. Firstly, characterization studies were utilized by FTIR, SEM and BET analysis. Then antimicrobial assays, drug release studies and in vitro cytotoxicity test were performed. A significant antimicrobial effect against both Gram (+) Staphylococcus aureus and Gram (-) Escherichia coli bacteria and a yeast Candida albicans were observed even in low exposure time periods. When antimicrobial effect of EU compared with commercially used agents, both antifungal and antibacterial activity of EU were found to be higher. Then, sustained drug release studies showed that approximately 55% of EU was released up to 50 h. This result proved the achievement of the molecular imprinting for an immobilization of molecules that desired to release on an area in a long-time interval. Finally, the in vitro cytotoxicity experiment performed with the mouse L929 cell line determined that the synthesized EU-imprinted BC nanocomposite was biocompatible.
摘要：
在这项研究中,一种新的生物复合材料，允许持续释放植物来源的抗微生物化合物被开发用于生物医学应用，以防止由对商业抗微生物剂有抗性的微生物引起的感染。为了这个目标,通过金属螯合单体印迹丁香酚（EU）的细菌纤维素（BC）-p（HEMA）纳米复合膜，MAH准备好了。首先,通过FTIR进行表征研究，SEM和BET分析。然后抗菌检测，进行了药物释放研究和体外细胞毒性测试。即使在低暴露时间内，也观察到对革兰氏（）金黄色葡萄球菌和革兰氏（-）大肠杆菌细菌以及白色念珠菌的显着抗菌作用。当欧盟的抗菌效果与商业使用的药物相比时，发现欧盟的抗真菌和抗菌活性均较高。然后，持续药物释放研究表明，大约55％的EU释放到50小时。该结果证明了分子印迹的实现，用于固定希望在长时间间隔内在区域释放的分子。最后,用小鼠L929细胞系进行的体外细胞毒性实验确定合成的EU印迹BC纳米复合材料是生物相容的。
